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Abstract:
Aims:  The main mechanism behind caffeine’s ergogenicity lies in its 
tendency to bind to adenosine A1 and A2A receptors.  However, other 
mechanisms might contribute to caffeine’s ergogenicity.  The aim of this 
investigation was to analyze the effects of caffeine on muscle oxygen 
saturation during exercise of increasing intensity. Methods: Thirteen 
healthy and active individuals volunteered to participate in a 
randomized, double blind, placebo-controlled crossover trial.  During two 
different trials, participants either ingested a placebo (cellulose) or 3 
mg/kg of caffeine.  After waiting for 60 min to absorb the substances, 
participants underwent a maximal ramp cycle ergometer test (25 
W/min). Near infrared spectrometers were positioned on each leg’s 
vastus lateralis to monitor tissue O2 saturation.  Blood lactate 
concentration was measured 1 min after the end of the exercise test. 
Results:  In comparison to the placebo, the ingestion of caffeine 
improved the maximal wattage (258±50 vs 271±54 W, respectively, P < 
0.001) and blood lactate concentration (11.9±3.8 vs 13.7±3.5 mmol/L, 
P = 0.029) at the end of the test.  Caffeine increased muscle oxygen 
saturation at several exercise workloads with a main effect found in 
respect to the placebo (F = 6.28, P = 0.029).  Peak pulmonary 
ventilation (124±29 vs 129±23 L/min, P=0.035) and VO2peak 
(3.18±0.70 vs 3.33±0.88 L/min, P=0.032) were also increased with 
caffeine.  Conclusion:  Acute ingestion of 3 mg/kg of caffeine improved 
peak aerobic performance while caffeine-induced changes seen in muscle 
oxygen saturation, pulmonary ventilation, and blood lactate 
accumulation suggest that these mechanisms might also contribute to 
caffeine’s ergogenic effect.
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1 ABSTRACT
2 Aims:  The main mechanism behind caffeine’s ergogenicity lies in its tendency to bind 
3 to adenosine A1 and A2A receptors.  However, other mechanisms might contribute to 
4 caffeine’s ergogenicity.  The aim of this investigation was to analyze the effects of 
5 caffeine on muscle oxygen saturation during exercise of increasing intensity. Methods: 
6 Thirteen healthy and active individuals volunteered to participate in a randomized, double 
7 blind, placebo-controlled crossover trial.  During two different trials, participants either 
8 ingested a placebo (cellulose) or 3 mg/kg of caffeine.  After waiting for 60 min to absorb 
9 the substances, participants underwent a maximal ramp cycle ergometer test (25 W/min). 
10 Near infrared spectrometers were positioned on each leg’s vastus lateralis to monitor 
11 tissue O2 saturation.  Blood lactate concentration was measured 1 min after the end of the 
12 exercise test. Results:  In comparison to the placebo, the ingestion of caffeine improved 
13 the maximal wattage (258±50 vs 271±54 W, respectively, P < 0.001) and blood lactate 
14 concentration (11.9±3.8 vs 13.7±3.5 mmol/L, P = 0.029) at the end of the test.  Caffeine 
15 increased muscle oxygen saturation at several exercise workloads with a main effect 
16 found in respect to the placebo (F = 6.28, P = 0.029).  Peak pulmonary ventilation 
17 (124±29 vs 129±23 L/min, P=0.035) and VO2peak (3.18±0.70 vs 3.33±0.88 L/min, 
18 P=0.032) were also increased with caffeine.  Conclusion:  Acute ingestion of 3 mg/kg of 
19 caffeine improved peak aerobic performance while caffeine-induced changes seen in 
20 muscle oxygen saturation, pulmonary ventilation, and blood lactate accumulation suggest 
21 that these mechanisms might also contribute to caffeine’s ergogenic effect.
22 Keywords: near infrared spectroscopy, muscle oxygenation, high intensity exercise, 
23 VO2max, cycling. 
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24 WHAT IS KNOWN ABOUT THIS SUBJECT 
25  The main mechanism behind caffeine’s ergogenicity lies in its tendency to bind to 
26 adenosine A1 and A2A receptors 
27  However, caffeine is a xanthine which acts on a wide range of molecular targets.  
28 Therefore, other mechanisms might contribute to caffeine’s ergogenicity.
29  Caffeine augments endothelium-dependent vasodilation by way of increased nitric 
30 oxide production and thus and it might lead to increased tissue blood flow and 
31 oxygen supply to the exercising muscle during exercise.
32 WHAT THIS STUDY ADDS
33  The acute ingestion of 3 mg of caffeine per kg of body mass was effective in 
34 increasing the maximal wattage obtained in a graded cycling test. 
35  This ergogenic effect was accompanied by increased VO2peak, blood lactate 
36 concentration, and peak pulmonary ventilation.  
37  Furthermore, a higher caffeine-induced muscle oxygen saturation was found in low-
38 to-moderate workloads, which allowed the obtaining of the end-point for muscle 
39 oxygen saturation associated to fatigue at higher exercise intensity.  This outcome 
40 indicates caffeine’s ability to enhance oxygen availability in the exercising muscle.
41
42
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43 INTRODUCTION
44 Caffeine (1,3,7-trimethylxanthine) is a substance naturally found in coffee, tea, and 
45 cocoa.  However, its potent ability to enhance physical performance and wakefulness has 
46 favored the inclusion of this stimulant in several over-the-counter medications and dietary 
47 supplements [1].  Caffeine has the capacity to improve performance in a wide-variety of 
48 exercise activities when ingested at low-to-moderate doses (3-9 mg/kg body mass [2,3]). 
49 Perhaps, this is the reason why caffeine is ingested by ~80% of competitive athletes [4].  While 
50 the ergogenic effect of caffeine to enhance sports performance is well-recognized [5], the 
51 physiological origin of caffeine’s ergogenicity is poorly understood.  The hydrophobic nature 
52 of caffeine results in a post-absorption distribution of the substance to all tissues of the body, 
53 making it difficult to accurately quantify its key mechanism of action during exercise [6].  
54 There is a consensus about caffeine antagonism of the adenosine receptors as the main 
55 mechanism behind the performance-enhancing effect of this substance [7].  Briefly, evidence 
56 in animal [8] and human models [9] supports the ability of caffeine to act as an adenosine A1 
57 and A2A receptor antagonist, reducing the adenosine-induced effect on neurotransmission and 
58 creating a greater dopaminergic drive [7].  However, the influence of caffeine on exercise 
59 performance cannot be only explained by its effects on the brain, as several other central and 
60 peripheral mechanisms can aid in producing a more potent ergogenic effect.  Other 
61 mechanisms, such as reduced muscle pain and perceived exertion [10], central stimulation of 
62 the respiratory medullary complex [11], fatty acid mobilization and oxidation [12], and local 
63 changes within the exercising muscle such as potassium ion attenuation in the interstitium and 
64 calcium iron release from the sarcoplasmic reticulum [6,13], have also been proposed to 
65 explain caffeine effects on physical performance.  
66 Caffeine also produces an indirect increase in serum adenosine concentration by 
67 competitively blocking adenosine receptors [14].  The increased availability of adenosine 
Page 5 of 23
British Pharmacological Society
British Journal of Clinical Pharmacology
British Journal of Clinical Pharm
acology
2
68 causes a generalized stimulation of chemoreceptors distributed throughout circulation and 
69 creates an increase in the sympathetic tone and the upsurge of circulating catecholamines [15].  
70 Although the direct effects of adenosine on the different vascular systems depend on the type 
71 of receptor that is stimulated [16], the main vascular effect of adenosine is vasodilation of the 
72 different blood beds via A2A stimulation.  In addition, acute administration of caffeine 
73 augments endothelium-dependent vasodilation by way of increased nitric oxide production 
74 [17].  Thus, caffeine might directly and indirectly produce vasodilation in the endothelium 
75 and in the vascular smooth muscle cells, which leads to increased tissue blood flow and 
76 oxygen supply to the exercising muscle during exercise.  To the best of our knowledge, there 
77 are no investigations that have measured the effect of caffeine on tissue oxygen saturation 
78 during exercise.  Thus, the aim of the current investigation was to analyze the effects of 
79 caffeine on oxygen saturation of the vastus lateralis during cycling of increasing intensity.  
80
81 MATERIALS AND METHODS
82 Participants. Thirteen healthy and active (>4 days of training per week; > 45 min per 
83 day) individuals volunteered to participate in this investigation. They had a mean ± standard 
84 deviation (SD) age of 32.5 ± 6.5 yr, height of 171 ± 8 cm, weight of 65.2 ± 11.4 kg, and peak 
85 oxygen uptake (VO2peak) of 49.7 ± 8.5 mL/kg/min. There were seven women in the sample 
86 who participated in the entire experiment in their luteal phase. All the participants were light 
87 caffeine consumers (< 50 mg of caffeine per day), non-smokers, and did not report any 
88 previous history of cardiopulmonary diseases nor musculoskeletal injuries reported in the 
89 previous three months. One week prior to the study, the participants were fully informed of 
90 the experimental procedures and gave their informed written consent to participate in the 
91 investigation.  The study was approved by the Camilo José Cela University Research Ethics 
92 Committee.
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93 Experimental design. A randomized, double blind, placebo-controlled and 
94 crossover experimental design was used in this study. Each participant took part in 2 
95 identical trials that were conducted 48 h apart to allow time for recovery and substance 
96 elimination.  The participants were randomly assigned to ingest an unidentifiable capsule 
97 either filled with 3 mg of caffeine per kg of body mass (Bulk Powders, United Kingdom) or 
98 with the same amount of cellulose as a placebo (Guinama, Spain).  The assigned capsule for 
99 each trial was administered with 150 mL of tap water 60 min before the onset of the 
100 experimental trials.  Each trial consisted of a graded maximal exercise test on a cycle 
101 ergometer (SNT Medical, Cardgirus, Spain) until volitional fatigue.  Ventilatory variables, 
102 heart rate, and muscle oxygen saturation were continuously measured during exercise to 
103 assess the effect of caffeine on these variables.  An alphanumeric code was assigned to each 
104 trial by an individual who was not involved in the study.  Investigators and participants were 
105 not aware of the assignment of the trials nor the substances under investigation. All trials 
106 were performed in a laboratory with constant ambient conditions (21.5 ± 0.3 ºC and 45 ± 2% 
107 relative humidity). 
108 Experimental protocol. A week prior to the onset of the experiments, participants were 
109 familiarized with all the research protocols twice and their body mass was measured (±50 g, 
110 Radwag, Poland) to calculate proper caffeine dosage.  During the familiarization protocols, 
111 skinfold thickness (Holtain Ltd, Bryberian, Crymmych, Pembrokeshire) was measured in the 
112 biceps, triceps and subscapular and supra-iliac areas to calculate body fatn [18] and on the 
113 vastus lateralis of both legs (right limb = 5.7 ± 2.5 mm, left limb = 5.6 ± 2.0 mm).  The day 
114 before each experimental trial, participants refrained from all sources of dietary caffeine, from 
115 strenuous exercise and alcohol, and adopted a standardized diet and fluid intake. All these 
116 standardizations were recorded in a diary during the first trial and later replicated in the second 
117 trial. 
Page 7 of 23
British Pharmacological Society
British Journal of Clinical Pharmacology
British Journal of Clinical Pharm
acology
4
118 On the day of the trials, participants arrived to the laboratory at 9.00 in a fed state (at 
119 least 3 hours have passed after their last meal) and the assigned experimental capsule was 
120 provided in an unidentifiable bag.  They immediately ingested the capsule with water. Then, 
121 they changed into a T-shirt, shorts and cleated shoes, and had a heart rate belt (Wearlink, 
122 Polar, Finland) attached to their chest.  At this time, a near infrared spectrometer (Moxy®, 
123 Fortiori Design LLC, Minnesota, USA) was positioned longitudinally on the musculus vastus 
124 lateralis of each lower limb, halfway between the greater trochanter and lateral epicondyle of 
125 the femur, to monitor tissue O2 saturation.  This device has been shown to be reliable in 
126 measuring local oxygen saturation during exercise (intraclass correlation coefficient of 0.77 
127 to 0.99; [19]).  The position of each spectrometer was marked with an indelible marking pen 
128 to assure inter-day positioning. In addition, the spectrometers were firmly attached to the skin 
129 with an elastic tubular net bandage positioned around the thigh (Vendafix, Favesam, Spain).  
130 The lack of spectrometer movement was tested during the warm-up.  The vastus lateralis was 
131 chosen as the location for the spectrometers because it is a part of the knee extensor group, 
132 which is the primary contributor to force production during the down stroke of the pedal [20] 
133 and it is a typical location used to assess muscle oxygenation during incremental cycling 
134 exercise [21].  After this step, the participants rested on a stretcher in a supine position for 60 
135 min to allow for the experimental substance to be absorbed.
136 After the resting period, participants performed a 10-min standardized warm-up on the 
137 cycle ergometer at 50 W and then exercise intensity was progressively increased by 25 W/min 
138 (ramp test) until volitional fatigue.  The pedaling frequency was individually chosen (between 
139 75 and 90 rpm) but maintained during the whole graded exercise test and replicated in both 
140 experimental trials.  The seat and handlebar positions on the cycle ergometer were chosen in 
141 the familiarization trials and replicated for each individual in both experimental trials.  
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142 Standardized encouragement and feedback were given to the participants in all trials by the 
143 same researcher who was blinded to the treatments.  
144 During the exercise test, pulmonary ventilation, end-tidal oxygen partial pressure and 
145 oxygen uptake (VO2), and heart rate were continuously measured and recorded by means of 
146 a breath-by-breath analyzer (Metalyzer 3B, Cortex, Germany). Certified calibration gases 
147 (16.0% O2; 5.0% CO2, Cortex, Germany) and a 3-L syringe were used to calibrate the gas 
148 analyzer and the flow meter before each trial.  In the graded exercise test, maximal wattage 
149 (Wmax) was recorded as the exercise load on the cycle ergometer at the moment that 
150 participants abruptly stopped pedaling or when an individual’s pedaling frequency was 
151 lower than 50 rpm.  VO2peak was defined as the highest VO2 value obtained during the test.  
152 The absolute value of VO2peak in the placebo trial was used to normalize the exercise 
153 intensity that represented each workload.  For this normalization, the VO2 of each workload 
154 was divided by the individual VO2peak in the placebo trial, and the relative load (i.e., % of 
155 placebo VO2peak) was then allocated to the nearest load by using 5% intervals.  At each 
156 workload, all variables were averaged every 15 s and the last 15 s of each stage were used as 
157 a representative value of the workload.  The exercise test was considered maximal and valid 
158 when the following end criteria were reached at the end of the test: VO2 stabilized despite 
159 increases in ergometric power, the respiratory exchange ratio was higher than 1.10, 
160 participant’s rating of perceived exertion (6-to-20 point Borg scale) was higher than 19 
161 points, and peak heart rate was greater than 80% of the age-adjusted estimate of maximal 
162 heart rate [22].  One minute after the end of the graded test, a blood sample was obtained 
163 from a participants’ fingertip to analyze blood lactate concentration (Lactate Pro 2, Arkay, 
164 Japan).  
165 Statistical Analysis.  The results of each trial were blindly introduced into the statistical 
166 package SPSS v 20.0 for later analysis.  Differences between the caffeine vs. placebo protocols 
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167 were determined by a two-way analysis of variance (substance × workload) with repeated 
168 measures.  After a significant F test (Geisser-Greenhouse correction for the assumption of 
169 sphericity), differences between the means were identified using Tukey’s HSD post hoc.  The 
170 difference in peak values of caffeine vs. placebo for all variables was identified with the 
171 Student’s T test for paired samples.  The significance level was set at P < 0.05 and all data 
172 were presented as means ± SD.  
173
174 RESULTS 
175 In comparison to the placebo, the ingestion of caffeine improved Wmax at the end of 
176 the ramp test by 5.2 ± 3.8% (258 ± 50 vs 271 ± 54 W, respectively, P < 0.001).  In addition, 
177 1 min after the end of the ramp test, blood lactate concentration was increased by 14.3 ± 3.6% 
178 with the ingestion of caffeine (11.9 ± 3.8 vs 13.7 ± 3.5 mmol/L, P = 0.029).  However, the 
179 rating of perceived exertion at the end of exercise was very similar very similar, regardless of 
180 whether a placebo or caffeine was ingested (19.3 ± 0.9 vs 19.2± 1.0, P = 0.800).  
181 During exercise, there was a main effect of caffeine on muscle oxygen saturation (F = 
182 6.28, P = 0.029) while the pairwise comparison detected differences between caffeine and 
183 placebo at 29 ± 3, 39 ± 3, 51 ± 2 and 61 ± 3% of placebo VO2peak (Figure 1).  Nevertheless, 
184 the lowest value of muscle oxygen saturation, obtained at the end of exercise, was not different 
185 between treatments (26.8 ± 14.5 vs 26.9 ± 14.5%, P = 0.295).  In pulmonary ventilation, a 
186 main effect of caffeine was not detected (F = 0.60, P = 0.460) but peak pulmonary ventilation 
187 was higher with caffeine by 6.1 ± 8.5% (124 ± 29 vs 129 ± 23 L/min, P = 0.035).  In end-tidal 
188 O2 partial pressure, there was no main effect of caffeine found (F = 0.10, P = 0.759) and peak 
189 O2 partial pressure remained unchanged with caffeine (115 ± 5 vs 115 ± 4 mmHg, P = 0.278).  
190 In VO2, there was no detected main effect of caffeine (F = 0.31, P = 0.589) but VO2peak was 
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191 increased by 4.5 ± 10.6% with caffeine (3.18 ± 0.70 vs 3.33 ± 0.88 L/min, P = 0.032).  In 
192 regards to heart rate, there was no main effect of caffeine (F = 3.77, P = 0.110) and peak heart 
193 rate remained unchanged with caffeine (173 ± 11 vs 173 ±11 beats/min, P = 0.403).  
194
195 DISCUSSION
196 The aim of the investigation was to analyze the effects of caffeine on muscle oxygen 
197 saturation during a graded maximal cycling test in healthy individuals.  This aim was designed 
198 to ascertain whether caffeine’s ergogenicity during endurance exercise is produced, at least in 
199 part, via increased oxygen supply to the exercising muscle, in addition to the well-contrasted 
200 mechanism via blockade of adenosine receptors in the brain [7].  The main outcomes of this 
201 investigation indicate that caffeine increased Wmax while also enhancing muscle oxygen 
202 saturation at 30-60% of VO2peak.  Although the caffeine-placebo comparison did not show 
203 an effect on muscle oxygen saturation at the highest workloads, the end-point value for muscle 
204 oxygen saturation, which characterizes muscle fatigue during cycling [21], was later obtained 
205 and at a higher exercise intensity with caffeine (i.e., 104.5% of placebo VO2peak, Figure 1).  
206 The acute ingestion of caffeine also increased VO2peak, peak pulmonary ventilation, and post-
207 exercise blood lactate concentration, suggesting that the ergogenic effect of caffeine was also 
208 driven by respiratory and metabolic pathways.  These results suggest that caffeine’s 
209 ergogenicity during an incremental cycling exercise relies on the multiple effects of this 
210 substance on body tissues and likely explain why caffeine has the capacity to increase 
211 performance in such a wide range of endurance exercise activities [1,23].  
212 The benefits of caffeine ingestion on high-intensity endurance cycling tests have been 
213 reported in the literature through original investigations [24–26] and meta-analysis [1,23,27].  
214 The magnitude of caffeine’s ergogenicity is typically higher in investigations that used time-
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215 to-exhaustion endurance protocols than in maximal graded or time trials [1,27].  Furthermore, 
216 it seems that the effect of caffeine on endurance performance is of similar magnitude in men 
217 and women [24] and may last for up to fifteen days  when the substance is ingested daily [26].  
218 Despite the consistency in the investigations that have reported an ergogenic effect of acute 
219 caffeine intake on endurance activities, there is a disparity of findings regarding the 
220 mechanism(s) behind the effects of caffeine.  Shen et al., [1], through a meta-analysis of 40 
221 articles, have reported that caffeine’s ergogenicity increases along with exercise duration.  
222 This finding is consiste t with that of Silveira et al., [25], who indicated that caffeine effects 
223 on endurance performance might be linked to an enhanced maintenance of maximal metabolic 
224 oxidative pathways.  However, ther investigations have found caffeine-induced effects on 
225 several variables associated with anaerobic energy systems [28–30] and a direct effect of 
226 caffeine on ventilation [11].  In the majority of these investigations, caffeine-induced changes 
227 have been related to an effect on the central nervous system via the direct competitive 
228 blockade of the adenosine receptors in the brain that inhibits the deleterious effects of 
229 adenosine and permits more external work [8].  Alternatively, caffeine has also been related 
230 to a direct effect on increasing muscle force production by way of an calcium release from the 
231 sarcoplasmic reticulum during muscle contractions and delayed potassium accumulation [6].  
232 The current manuscript presents an additional mechanism of action that might help to 
233 understand the ergogenic effect of caffeine on endurance exercise.  In the caffeine trial, muscle 
234 oxygen saturation was enhanced with caffeine at 30-60% of VO2peak.  Although the statistical 
235 significance of this effect disappeared at higher workloads, there was a main effect of caffeine 
236 on muscle oxygen saturation in the caffeine trial that indicated higher oxygen availability in 
237 the exercising muscle.  While endurance training habitually yields enhanced oxygen 
238 utilisation within the muscle, which is translated into lower muscle oxygen saturation [31], 
239 the ingestion of caffeine produced higher muscle oxygen saturation, which reflected enhanced 
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240 blood oxygen supply to the exercising muscle.  Interestingly, the end-point of muscle oxygen 
241 saturation, obtained in the moment of volitional fatigue, was similar in caffeine and placebo 
242 trials despite the workload was significantly higher with caffeine, suggesting that the “margin” 
243 of improved tissue oxygenation due to caffeine allowed participants to cycle longer and at a 
244 higher exercise intensity in the caffeine trial.  Although the causes for the higher muscle 
245 oxygen saturation with caffeine are not evident from our data, the unchanged values of 
246 pulmonary ventilation, end-tidal oxygen partial pressure, and VO2 at submaximal workloads 
247 suggest that the load of oxygen at the alveolar level and the oxidative capacity of the 
248 exercising muscles were not modified with this stimulant.  If these two factors were likely 
249 unchanged with caffeine ingesti n, the alternative hypothesis for the physiological process 
250 that induced higher muscle oxygen saturation might be related to an improved blood flow to 
251 the muscle.  In fact, this theory has scientific support due to the potential vasodilation effects 
252 of caffeine at the endothelial level [17] and o  smooth muscle cells [16], or indirectly through 
253 the increased concentration of adenosine once caffeine blocks its receptors in the brain [32].  
254 This is the first investigation that shows an effect of caffeine on muscle oxygenation during 
255 exercise and requires further investigation.  
256 The current investigation presents some limitations, which should be discussed in 
257 order to understand the practical application of the results.  First, we used a ramp exercise test 
258 to determine the effect of caffeine on muscle oxygen saturation during endurance exercise.  
259 However, this protocol of increasing exercise intensity is not representative of any endurance 
260 competition.  Thus, the efficacy of caffeine in increasing tissue oxygen saturation should be 
261 confirmed by using exercise routines more applicable to sports before this mechanism is used 
262 to explain the ergogenic effect of caffeine in endurance sports.  Second, we placed the near-
263 infrared spectrometers on the vastus lateralis, which only represents a small portion of the 
264 muscles involved in pedaling.  To assure the effect of caffeine on tissue oxygenation during 
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265 cycling, the measurement of muscle oxygen content should be made in other leg muscles.  
266 Although the spectrometer used in this investigation is a valid and reliable tool for assessing 
267 local oxygen saturation, it has been found that its reliability is reduced along with exercise 
268 intensity [19].  This lower reliability at higher exercise intensities might explain the lack of 
269 effect of caffeine on this variable at exercise intensities > 60% VO2peak.  Last, we used only 
270 a dose of caffeine (i.e., 3 mg/kg) and thus, we are unable to determine whether there is a dose-
271 response effect of caffeine on muscle oxygen saturation.  Despite these limitations, this 
272 investigation is innovative and can be used to further the understanding caffeine’s ergogenic 
273 effect on endurance exercise performance.   
274 In summary, the results of this investigation indicate that the acute ingestion of 3 mg 
275 of caffeine per kg of body mass was effective in increasing the maximal wattage obtained in 
276 a graded cycling test by 5.2 ± 3.8%.  This ergogenic effect was accompanied by increased 
277 VO2peak, blood lactate concentration, and peak pulmonary ventilation, which represent 
278 effects found in previous investigations [26,33], and suggest that caffeine’s ergogenicity seen 
279 in maximal intensity exercise is, at least in part, driven by these changes.  Furthermore, a 
280 higher caffeine-induced muscle oxygen saturation was found in low-to-moderate workloads, 
281 which allowed the obtaining of the end-point for muscle oxygen saturation associated to 
282 fatigue at higher exercise intensity.  This outcome indicates caffeine’s ability to enhance 
283 oxygen availability in the exercising muscle, which serves as another potential explanation 
284 for the well-evidenced ergogenic effect of caffeine on endurance performance.  Further 
285 investigation is necessary to determine whether this effect of caffeine is present during 
286 endurance exercise sports or in high-intensity intermittent disciplines.
287
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407 Figure 1.  Muscle oxygen saturation during a maximal graded cycling test after the ingestion 
408 of 3 mg·kg -1 of caffeine or a placebo.  Data are mean ± standard deviation for 13 healthy and 
409 active individuals.
410 (*) Caffeine different from placebo at P < 0.05. 
411
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413 Figure 2.  Pulmonary ventilation, end-tidal O2 partial pressure, and O2 uptake during a 
414 maximal graded cycling test after the ingestion of 3 mg·kg -1 of caffeine or a placebo.  Data 
415 are mean ± standard deviation for 13 healthy and active individuals. 
416 (†) Peak value with caffeine different from peak value with placebo at P < 0.05. 
417
418
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